Form 8-K · Current Report · Filed 2025-11-03
Halozyme Reports Strong Q3 2025 Financial Results and Announces CFO Transition
Halozyme Therapeutics, Inc. reported strong financial results for the third quarter of 2025, with a 22% year-over-year increase in total revenue to $354 million, driven by a 52% increase in royalty revenue to $236 million. Net income rose 28% to $175 million, and non-GAAP diluted EPS increased 35% to $1.72. The company also raised its 2025 financial guidance, projecting total revenue growth of 28% to 35% and non-GAAP diluted EPS growth of 44% to 54%. Additionally, Halozyme announced that CFO Nicole LaBrosse will depart by March 30, 2026, to pursue a new professional opportunity, with a successor search currently underway.
- Filer
- Halozyme Therapeutics Inc. HALO · NASDAQ
- Filed
- Accession
- 0001159036-25-000044
- CIK
- 0001159036
- Signal
- High impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Results of Operations and Financial Condition
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Market reaction
Close before filing
$65.19
Next session
+4.4%
Since filing
+69.1%
Latest close
$110.24
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from HALO reporting the same item, with the next session's move:
About Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc. is a biopharmaceutical company that specializes in developing and commercializing treatments focused on enhanced subcutaneous drug delivery. The company's proprietary technology, ENHANZE, aims to improve the efficacy and convenience of existing therapies by facilitating faster drug absorption and reducing the need for intravenous administration. Halozyme partners with major pharmaceutical companies to integrate its technology with a variety of treatments, significantly impacting the oncology, immunology, and genetic disorder sectors. This collaboration model helps expand the reach of its technology across multiple therapeutic applications. Based in San Diego, California, Halozyme is noted for its innovative approach to drug delivery, contributing to the broader pharmaceutical industry's efforts to improve patient experiences and optimize medical outcomes. As a significant player in the biopharmaceutical landscape, Halozyme's advancements continue to drive interest and growth within the market, underscoring the vital role of drug delivery technology in modern medicine.
Never miss another HALO filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.